1. Medtech Insight

Siemens Claims A First With Test That Can Quantify Neutralizing Antibodies To COVID-19

 
• By Phil Greenfield

The test measures the relative level of antibodies, which could aid vaccine rollout.

Medical doctor or laborant holding tube with covid vaccine and microscope. Coronavirus 2019-nCoV COVID concept.

Siemens Healthineers AG has CE marked a SARS-CoV-2 IgG antibody test, which it claims is the first diagnostic from a major IVD company to measure the quantity of neutralizing antibodies. This will be important in measuring the effectiveness of COVID-19 vaccines and determining whether broad vaccination programs are working. The company has submitted the test to the US Food and Drug Administration under an emergency use authorization.

There are numerous quantitative tests for SARS-CoV-2 antibodies available, but Siemens Healthineers claims other quantitative tests from major suppliers do...

More from R&D

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 
• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Milner Pitch Day: Multiomic Pathology, Microcancer Avatars And Cell Morphology Intelligence

 
• By Natasha Barrow

The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.

Novel Pathway For Combined Drug/IVD Trials Wins Backing Of EU Nations

 
• By Vibha Sharma

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By Marion Webb

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

More from Business